scholarly journals Early Safety and Efficacy of Sapien 3 20 mm Transcatheter Heart Valve Implantation in Small Japanese Body Size

2018 ◽  
Vol 21 (5) ◽  
pp. E341-E344
Author(s):  
Kentaro Meguro ◽  
Ryota Kakizaki ◽  
Takuya Hashimoto ◽  
Tomoyoshi Yanagisawa ◽  
Toshimi Koitabashi ◽  
...  
Keyword(s):  
Body Size ◽  
Aortic Valve ◽  
Heart Valve ◽  
Small Body ◽  
Japanese Patients ◽  
Aortic Valve Area ◽  
Small Body Size ◽  
Transcatheter Heart Valve ◽  
Sapien 3 ◽  
Valve Implantation

Background: Transcatheter aortic valve implantation (TAVI) is effective in treating severe aortic stenosis in inoperable or high-risk surgical patients, however, the little is known about outcomes after Sapien 3 20 mm transcatheter heart valve (THV) implantation. The purpose of this study was to investigate the short term outcomes of Sapien 3 20 mm THV implantation in Japanese people with a small body size. Methods: We retrospectively collected the hospital records of consecutive patients who underwent TAVI using the Sapien 3 20 mm THV between October 2016 and March 2017. Clinical and echocardiographic data from before and one week after TAVI were collected. Results: Six Japanese patients (all female, mean age 89 ± 5 years, body surface area [BSA] 1.29 ± 0.16m2) received a Sapien 3 20 mm THV. All the procedures were feasible and successful, and the 30-day mortality rate was 0%. The functional class and the echocardiographic findings significantly improved (aortic valve area, 0.5 ± 0.1 cm2 to 0.8 ± 0.1cm2; mean pressure gradient, 55 ± 15 mmHg to 19 ± 7 mmHg; P = .043, respectively). However, the values of the indexed effective orifice area in all patients after Sapien 3 20 mm THV implantation were less than 0.85 cm2/m2, suggesting prosthesis-patient mismatch (PPM). Conclusions: The implantation of a Sapien 3 20 mm THV was safe and effective in high surgical risk elderly Japanese patients with a small body size. PPM after Sapien 3 20mm THV may be prevalent among Asians with small body sizes. Careful clinical follow-up will be necessary after Sapien 3 20 mm THV implantation.

scholarly journals TCT-831 Transcatheter Aortic Valve Implantation in Patients of Small Body Size

2012 ◽  
Vol 60 (17) ◽  
pp. B241-B242
Author(s):  
Yusuke Watanabe ◽  
Kentaro Hayashida ◽  
Thierry Lefèvre ◽  
Bernard Chevalier ◽  
Thomas Hovasse ◽  
...  
Keyword(s):  
Body Size ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Small Body ◽  
Small Body Size ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals 168: Transcatheter aortic valve implantation in patients with small body size

2013 ◽  
Vol 5 (1) ◽  
pp. 55
Author(s):  
Yusuke Watanabe ◽  
Kentaro Hayashida ◽  
Thierry Lefèvre ◽  
Bernard Chevalier ◽  
Thomas Hovasse ◽  
...  
Keyword(s):  
Body Size ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Small Body ◽  
Small Body Size ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation in patients of small body size

2014 ◽  
Vol 84 (2) ◽  
pp. 272-280 ◽  
Author(s):  
Yusuke Watanabe ◽  
Kentaro Hayashida ◽  
Thierry Lefèvre ◽  
Bernard Chevalier ◽  
Thomas Hovasse ◽  
...  
Keyword(s):  
Body Size ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Small Body ◽  
Small Body Size ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals Case Report: Sapien 3 Transcatheter Heart Valve Embolization: Cause, Management, and Redo

2021 ◽  
Vol 8 ◽  
Author(s):  
Mi Chen ◽  
Barbara E. Stähli ◽  
Jonathan M. Michel ◽  
Miriam Brinkert ◽  
Felix C. Tanner ◽  
...  
Keyword(s):  
Case Report ◽  
Aortic Valve ◽  
Heart Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve ◽  
Rapid Pacing ◽  
Aortic Valve Implantation ◽  
Sapien 3 ◽  
Valve Implantation

The transcatheter heart valve (THV) embolization is a rare but challenging complication in transcatheter aortic valve implantation (TAVI). We report the case of an 81-year-old man with Sapien 3 embolization caused by interrupted rapid pacing. In this setting, we describe the embolized THV management and the technique of the second Sapien 3 implantation.

OP-98 Aortic Valve Implantation with Edwards SAPIEN 3 Transcatheter Heart Valve: Two Cases In Azerbaijan

2015 ◽  
Vol 115 ◽  
pp. S43-S44
Author(s):  
Anar Emrah ◽  
Arzu Murselova ◽  
Eldar Veliyev ◽  
Valeh Mammadov ◽  
Nazim Salimov ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Heart Valve ◽  
Transcatheter Heart Valve ◽  
Edwards Sapien ◽  
Aortic Valve Implantation ◽  
Sapien 3 ◽  
Valve Implantation

scholarly journals Incidence and predictors of prosthesis–patient mismatch after TAVI using SAPIEN 3 in Asian: differences between the newer and older balloon-expandable valve

Open Heart ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. e001531
Author(s):  
Masaki Miyasaka ◽  
Norio Tada ◽  
Masataka Taguri ◽  
Shigeaki Kato ◽  
Yusuke Enta ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Strong Predictor ◽  
Multivariate Logistic Regression Analysis ◽  
Asian Population ◽  
Effective Orifice Area ◽  
Aortic Valve Area ◽  
Complication Rates ◽  
Number Of Patients ◽  
Transcatheter Heart Valve ◽  
Sapien 3

BackgroundThe balloon-expandable SAPIEN 3 (S3) is superior to the older-generation balloon-expandable SAPIEN XT (XT) in a lower incidence of paravalvular aortic regurgitation, lower complication rates and better survival in transcatheter aortic valve implantation (TAVI). However, prosthesis–patient mismatch (PPM) more frequently occurs in S3 than XT. Further, little information is available on PPM after TAVI using S3 in Asians. This study aims to determine the incidence and predictors of PPM in S3 by focusing on the difference between S3 and XT using data from a Japanese multicentre registry.MethodsFrom the Optimised transCathEter vAlvular iNtervention-TAVI (OCEAN-TAVI) registry, 2134 patients undergoing TAVI using S3 or XT were included. PPM was defined as moderate if ≧0.65 but ≦0.85 cm2/m2 or severe if <0.65 cm2/m2 at the indexed effective orifice area by postprocedural echocardiography.ResultsThe incidence of moderate and severe PPM in S3 was 13.3% and 1.3%, respectively. The 20 mm transcatheter heart valve (THV) was more frequently used in S3 than XT (7.4% vs 2.4%, p<0.0001). PPM was more frequently observed in S3 than XT (14.7% vs 8.8%, p<0.0001). Multivariate logistic regression analysis revealed S3 predicted PPM (OR 1.92 (95% CI 1.35 to 2.74), p=0.0003). The mutual predictors for PPM between S3 and XT were younger age, larger body surface area, smaller aortic valve area, no balloon postdilatation and the use of 20 mm and 23 mm THV. When comparing 23 mm, 26 mm and 29 mm S3, the ORs of 20 mm S3 were 5.67 (95% CI 2.88 to 11.12), 19.24 (95% CI 8.13 to 46.86) and 51.03 (95% CI 12.28 to 280.77), respectively.ConclusionsThe incidence of PPM after TAVI using S3 was 14.6% overall in this Asian population. PPM was more frequently observed in S3 than XT. A considerable number of patients were treated by the 20 mm S3 in an Asian cohort. The 20 mm THV was identified as a strong predictor for PPM.

Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States

2021 ◽  
Vol 14 (9) ◽  
Author(s):  
Tamim M. Nazif ◽  
Thomas J. Cahill ◽  
David Daniels ◽  
James M. McCabe ◽  
Mark Reisman ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Clinical Outcomes ◽  
Valve Replacement ◽  
Heart Valve ◽  
Transcatheter Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve ◽  
Sapien 3 ◽  
Transcatheter Valve

Background: Paravalvular regurgitation (PVR) after transcatheter aortic valve replacement is associated with adverse clinical outcomes. The SAPIEN 3 Ultra (Ultra) is a new generation balloon-expandable transcatheter heart valve with a modified external skirt that is designed to reduce PVR, but reports of clinical and echocardiographic outcomes are limited. The aim of this study was to compare short-term outcomes of patients undergoing transcatheter aortic valve replacement with the Ultra and the original SAPIEN 3 (S3) transcatheter heart valve in a large national registry. Methods: Data from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry was used to compare patients who underwent elective, transfemoral transcatheter aortic valve replacement with the Ultra or S3 transcatheter heart valve. Clinical and echocardiographic outcomes were analyzed in a propensity-matched cohort at discharge and 30 days. Results: Patients who underwent transcatheter aortic valve replacement with Ultra (N=1324) from January 2019 to February 2020 were propensity score–matched with patients treated with S3 (N=32 982) during the same period, resulting in 1324 matched pairs. There was no difference in the rate of device success between patients treated with Ultra and S3 (97.1% versus 98.0%, P =0.11). At hospital discharge, PVR was significantly reduced with Ultra compared with S3, with mild PVR in 9.0% versus 13.9% and moderate or greater PVR in 0.1% versus 0.4% (overall P <0.01). At 30 days, there were no differences between Ultra and S3 recipients in the rates of all-cause mortality or stroke (1.8% versus 2.8%, P =0.10), major vascular complications (1.1% versus 1.0%, P =0.84), or permanent pacemaker implantation (6.4% versus 6.2%, P =0.81). Conclusions: In this propensity-matched analysis from the Transcatheter Valve Therapy Registry, the Ultra transcatheter heart valve was associated with similar procedural and 30-day clinical outcomes, but reduced incidence of PVR, compared with S3. The clinical benefit of less PVR should be evaluated in longer-term studies.

Sign in / Sign up

Export Citation Format

Share Document